# Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES

Study · id `cardio:ct-nct04135989` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04135989](<https://clinicaltrials.gov/study/NCT04135989>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04135989

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2106 participants.

## Technical summary

Registry record NCT04135989. Randomized; single masking; primary purpose treatment. Start 2020-01-01 (actual); primary completion 2021-10-24 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2106 participants (planned count; ClinicalTrials.gov record NCT04135989, source copy `cardio:ctgov-nct04135989-2024-02-23`, retrieved 2026-10-26)
- Started: 2020-01-01 (actual) (ClinicalTrials.gov record NCT04135989, source copy `cardio:ctgov-nct04135989-2024-02-23`, retrieved 2026-10-26)
- Primary completion: 2021-10-24 (actual) (ClinicalTrials.gov record NCT04135989, source copy `cardio:ctgov-nct04135989-2024-02-23`, retrieved 2026-10-26)
- Completion: 2024-10-24 (anticipated) (ClinicalTrials.gov record NCT04135989, source copy `cardio:ctgov-nct04135989-2024-02-23`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT04135989, source copy `cardio:ctgov-nct04135989-2024-02-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04135989-2024-02-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES
- Acronym: PARTHENOPE
- Condition: Coronary Artery Disease
- Condition: Acute Coronary Syndrome
- Condition: Chronic Coronary Syndrome
- Condition: Myocardial Infarction
- Intervention (Device): Percutaneous coronary intervention with implantation of amphilimus-eluting stents for coronary artery disease.
- Intervention (Device): Percutaneous coronary intervention with implantation of everolimus-eluting stents for coronary artery disease.
- Intervention (Drug): Personalized DAPT duration
- Intervention (Drug): Standard DAPT duration
- Lead sponsor: Federico II University
- Lead sponsor class: OTHER
- Collaborator: AdvicePharma Group
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: Federico II University (`cardio:org-federico-ii-university`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Polymer-free versus biodegradable-polymer drug-eluting stent in patients undergoing percutaneous coronary intervention: an assessor-blind, non-inferiority, randomised controlled trial (`cardio:pubmed-39773824`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Personalized or Standard Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: The PARTHENOPE Randomized Trial (`cardio:pubmed-40892607`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 3471095eeda45ada4fbfae1d74a96822d432b1b350da67bd3b1d21fcfd148471
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
